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New animal models are greatly needed in interstitial cystitis/painful bladder syndrome (IC/PBS) research. We recently developed
a novel transgenic cystitis model (URO-OVA mice) that mimics certain key aspects of IC/PBS pathophysiology. This paper aimed
to determine whether URO-OVA cystitis model was responsive to intravesical dimethyl sulfoxide (DMSO) and if so identify the
mechanisms of DMSO action. URO-OVA mice developed acute cystitis upon adoptive transfer of OVA-speciﬁc OT-I splenocytes.
Compared to PBS-treated bladders, the bladders treated with 50% DMSO exhibited markedly reduced bladder histopathology and
expressionofvariousinﬂammatoryfactormRNAs.IntravesicalDMSOtreatmentalsoeﬀectivelyinhibitedbladderinﬂammationin
a spontaneous chronic cystitis model (URO-OVA/OT-I mice). Studies further revealed that DMSO could impair eﬀector T cells in
adose-dependentmannerinvitro.Takentogether,ourresultssuggestthatintravesicalDMSOimprovesthebladderhistopathology
of IC/PBS patients because of its ability to interfere with multiple inﬂammatory and bladder cell types.
1.Introduction
IC/PBS is a chronic inﬂammatory condition of the urinary
bladder characterized by pelvic pain, irritative voiding symp-
toms (frequency, urgency, and nocturia), and sterile and
cytologically normal urine [1, 2]. The symptoms of IC/PBS
are often associated with signiﬁcant fatigue, depression,
anxiety, and suicidal tendency [3, 4], and thus aﬀect every
aspectofanindividual’slife.AlthoughtheetiologyofIC/PBS
remains unknown, many theories have been proposed
including mast cell activation, sensory neuron irritation,
inﬂammation, and autoimmunity [2, 5–7]. Accordingly,
IC/PBS models reﬂecting various pathophysiological path-
ways have been developed [8]. Among IC/PBS models, the
rodent model of experimental autoimmune cystitis (EAC)
[9] in which animals develop cystitis after immunization
with bladder homogenate, represents one of the most
actively used models in IC/PBS research [9–13]. Although
this conventional EAC model can reproduce many clinical
correlates seen in IC/PBS, this model does not facilitate the
studies of detailed mechanisms because of its lack of deﬁned
self-antigen(Ag)anditscorrespondingTcellreceptor(TCR)
speciﬁcity. To improve this model, we recently developed
a novel transgenic EAC model, designated as URO-OVA
mice [14]. URO-OVA mice express a membrane form of
the model Ag ovalbumin (OVA) as a self-Ag on the bladder
urothelium driven by the uroplakin II gene promoter and
develop bladder inﬂammation upon introduction of OT-I
CD8+ Tcellsthatexpressthetransgenic TCRspeciﬁcforH2-
Kb/OVA257–264 epitope [15]. The inﬂamed bladder resembles
the acute phase of IC/PBS histopathology as manifested by
prominent cellular inﬁltration, interstitial edema, mucosal
hyperemia, and high mast cell counts [14]. The inﬂamed
bladder also resembles neurogenic inﬂammation as elevated
mast cell- and sensory neuron-derived inﬂammatory factors
such as tumor necrosis factor (TNF)-α,n e r v eg r o w t hf a c t o r
(NGF), and substance P are detectable in the bladder prior
to the detection of histological changes [14]. In addition,
URO-OVA/OT-I mice, a derived line of URO-OVA mice
after crossed with OT-I mice, can spontaneously develop2 Journal of Biomedicine and Biotechnology
bladderinﬂammationwithpredominantcellularinﬁltration,
epithelial hyperplasia, and high mast cell counts [14], which
are the characteristics of the chronic phase of IC/PBS. To
dat e,theUR O-O V Acy stitismod elsha v ep r o v e nt obeuniq ue
and reproducible, permitting controlled studies on bladder
inﬂammation including antibladder inﬂammatory studies
[16, 17].
Due to its diverse pharmacologic properties, DMSO has
been used for the treatment of various diseases including
IC/PBS [18, 19]. Since approved by the U.S. Food and
Drug Administration (FDA) in 1978, intravesical DMSO
has served as one of the mainstays in the pharmacologic
treatment of IC/PBS. Although its mechanisms of action
have not yet been fully elucidated, intravesical DMSO
has shown its favorable eﬀects on treating both classic
and nonulcer IC/PBS patients [20–23]. Intravesical DMSO
relieves pain and voiding symptoms likely via its properties
of anti-inﬂammation and mast cell stabilization [24, 25]. In
a protamine sulfate-induced rat cystitis model, intravesical
DMSOhasalsobeendemonstratedtobeeﬀectiveontreating
non-bacterial bladder inﬂammation [26, 27]. Studies in
vitro have further demonstrated that DMSO could inhibit
stretch-activated ATP release by bladder urothelial cells from
IC/PBS patients [28], relax rabbit bladder detrusor muscle
contractility [29], improve rat bladder muscle compliance
[30], and increase rat bladder sensory aﬀerent neuron release
of nitric oxide [31]. In this study, we used transgenic EAC
models to evaluate the eﬀect of intravesical DMSO on
treatingautoimmunecystitis.WeobservedthatDMSOcould
inhibit both acute and chronic autoimmune cystitis in vivo
and eﬀector T cell activity in vitro. Our results support
the use of intravesical DMSO for the treatment of IC/PBS
patients and provide a potential mechanism underlying the
DMSO action.
2.MaterialsandMethods
2.1. Mice. URO-OVA mice (B6 and Thy1.2 background)
were developed in our laboratory and used to provide an
acuteEACmodel[14].URO-OVA/OT-Imiceweregenerated
through crossbreeding of URO-OVA mice with OT-I mice
(B6 background), a transgenic line originally generated by
KurtsandassociatesthatexpressestheCD8+ TCR speciﬁc for
Kb/OVA257–264 epitope [15], and used to provide a chronic
EAC model [14]. Female mice were used due to their
feasibility for intravesical procedures. In addition, OT-I mice
with both B6 and Thy1.1 backgrounds were used to provide
eﬀector T cells for cystitis induction. Mice were used at 8–10
weeks. All mice were housed in a pathogen-free facility at the
University of Iowa Animal Care Facility and used according
to the procedures approved by University of Iowa Animal
Care and Use Committee.
2.2. Cystitis Induction and DMSO Treatment. As described
previously [14, 17], OT-I splenocytes (Thy1.1) were pre-
pared, activated with OVA257–264 peptide in vitro, and
transferred i.v. into URO-OVA mice (Thy1.2) for acute
cystitis induction. Each mouse received 1 × 106 preactivated
Splenocytes
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Figure 1: Cystitis induction and intravesical DMSO treatment
schedule in URO-OVA mice. URO-OVA mice (Thy1.2) were
transferred i.v. with in vitro preactivated OT-I splenocytes (Thy1.1)
for cystitis induction at day 0, treated intravesically (i.b.) with 50%
DMSO at days 1, 4, and 7 and sacriﬁced for analysis at day 10.
SIINFEKL: OVA257–264 peptide.
OT-I splenocytes at day 0. DMSO (Fisher Scientiﬁc, Fair
Lawn, New Jersey) was dissolved in PBS at a 50% concen-
tration and used as an intravesical therapeutic agent. Mice
were anesthetized i.p. with 100μL of a mixture solution
of ketamine (87.5mg/kg) and xylazine (12.5mg/kg). The
bladder was then catheterized via the urethra with a 24-
gauge plastic intravenous cannula and instilled with 50 μL
of 50% DMSO solution through the cannula for 1 hour.
Control bladders were instilled with 50μL of PBS. In our
previous studies, URO-OVA mice developed acute cystitis
with peak inﬂammation at 7–14 days after cystitis induction
w h e r e a sU R O - O V A / O T - Im i c es p o n t a n e o u s l yd e v e l o p e d
chronic cystitis at 10 weeks of age that sustained for at
least 4 months [14]. Based on these observations, URO-OVA
mice were treated at 1, 4, and 7 days after cystitis induction
and sacriﬁced at day 10 for analysis (Figure 1). Accordingly,
URO-OVA/OT-I mice were treated once weekly for a total of
3 treatments staring at week 10 and sacriﬁced 3 days after last
treatment for analysis.
2.3. Bladder Histology. The standard histology was per-
formed as described previously [14, 17]. Brieﬂy, bladder
sections were paraﬃn-embedded, deparaﬃned, stained with
hematoxylin and eosin (H&E) solution, and photographed
using an Olympus BX-51 microscope. Bladder inﬂammation
was scored according to the criteria established in our
previous studies: 1+ (mild inﬁltration with no or mild
edema), 2+ (moderate inﬁltration with moderate edema),
and 3+ (moderate to severe inﬁltration with severe edema)
[14, 17].
2.4. Bladder Cell Flow Cytometry. Bladder single-cell sus-
pensions were prepared through mechanical dispersion as
described previously [14, 17] .C e l l sw e r ew a s h e dw i t hJournal of Biomedicine and Biotechnology 3
stainingbuﬀer(1%FBS,0.09%(w/v)NaN3 inMg2+
− andCa2+
−
free PBS), double stained with a FITC-CD8 antibody (eBio-
science, San Diego, California) and a PE-Thy1.1 antibody
(eBioscience), ﬁxed in 2% formalin, and analyzed using a
FACScanequippedwithCellQuestsoftware(BDBiosciences,
Franklin Lakes, New Jersey). Post acquisition analyses were
carried out using FlowJo software (Tree Star Inc, Ashland,
Oregan).
2.5. Bladder RT-PCR. As described previously [14, 17], bla-
dder total RNAs were extracted using Qiagen RNAeasy Kit
(Qiagen, Valencia, California) and used for cDNA synthe-
sis by Invitrogen Superscript III RNase H Reverse Trans-
criptase (Carlsbad, California) and Oligo dT. The cDNA
products were then processed for PCR ampliﬁcation using
sequence-speciﬁc primer pairs and Invitrogen Taq DNA
polymerase. The following primer pairs were used: 5 -
TGAACGCTACACACTGCATCT and 5 -GACTCCTTT-
TCCGCTTCCTGA for IFN-γ (459bp), 5 -CAAGAAGGA-
ATGGGTCCAGA and 5 -TGAGGTGGTTGTGGAAAAGG
for MCP-1 (175bp), 5 -CTGTGGACCCCAGACTGTTT
and 5 -CACTGAGAACTCCCCCATGT for NGF (194bp),
5 -CGTCAGCCGATTTGCTATCT and 5 -CGGACTCCG-
CAAAGTCTAAG for TNF-α (206bp), 5 -GTTCTCTGG-
GAAATCGTGGA and 5 -GGAAATTGGGGTAGGAAGGA
for IL-6 (339bp), and 5 -GTTCCAGTATGACTCCACT and
5 -GTGCAGGATGCATTGCTG for GAPDH (321bp). The
PCR kinetics for each of these molecules was initially estab-
lished to achieve a desirable discrepancy between the control
PBS-treated bladders and the DMSO-treated bladders. Based
on the established kinetics, 30 cycles were used for GAPDH,
36 cycles were used for IFN-γ,M C P - 1 ,N G F ,a n dT N F - α,a n d
40cycleswereusedforIL-6.TheDNAfragmentswererunon
a 1% agarose gel and imaged using EpiChemi digital image
analysis system (UVP Inc., Upland, California).
2.6. Eﬀector T Cell Growth Inhibition and Colorimetric
MTT Assay. OT-I splenocytes were prepared and incubated
with various concentrations of DMSO (ranging 1.563%–
75%) in a 96-well ﬂat-bottom plate at 4 × 105 cells/well
in 200μL of RPMI 1640 medium containing 10% fetal
bovine serum, 100units/mL of penicillin and 100μL/mL of
streptomycin. Cells treated with PBS were used as a control.
After incubation for 24 hours, 20μLo fM T T( 5 m g / m L ;
Sigma, St. Louis, Missouri) was added to each well and the
incubation continued for 4 hours. The medium overlying
cellswasthenaspiratedandcellsweresolubilizedwith200μL
of DMSO. The optical density was read at 570nm. Percent of
cell growth inhibition was calculated and presented as mean
± standard deviation of 5 duplicate wells referring to PBS-
treated wells (100% growth).
2.7. Eﬀector T Cell Apoptosis and Flow Cytometry. OT-
I splenocytes were prepared and incubated with various
concentrations of DMSO (ranging 1.563%–25%) in the
above-mentioned culture medium for 2 hours. Cells treated
with PBS were used as a control. After incubation, cells were
double stained with FITC-annexin V (BD Biosciences) and
propidium iodide, followed by ﬂow cytometry as described
previously [17].
2.8. Statistical Analysis. Student’s t-Test (StatView 4.5 soft-
ware, SAS Institute Inc., Cary, North Carolina) was used to
determine statistical signiﬁcance for bladder T cell inﬁltra-
tion and growth inhibition. A P-value of <. 05 was consi-
dered statistically signiﬁcant.
3. Results
3.1.IntravesicalDMSOTreatmentReducesBladderHistopath-
ology in Acute Autoimmune Cystitis. To evaluate the eﬀect
of DMSO on treating acute autoimmune cystitis, URO-OVA
mice (Thy1.2) were transferred i.v. with preactivated OT-I
splenocytes (Thy1.1) for cystitis induction at day 0, treated
intravesically with 50% DMSO at days 1, 4, and 7 and
sacriﬁced for analysis at day 10 (Figure 1). Compared to the
normal bladders (Figure 2(a)), adoptive transfer of preacti-
vated OT-I splenocytes induced clear bladder histopathology
seen in the control PBS-treated bladders (Figure 2(b);s c o r e :
3+). The inﬂamed bladders showed prominent cellular
inﬁltration, edema, and hyperemia in the lamina propria.
Compared to the PBS-treated bladders, the DMSO-treated
bladders exhibited markedly reduced histopathology with
minimum deﬁned morphologic changes (Figure 2(c);s c o r e :
< 1+).Thenormalbladderstreatedwith50%DMSOshowed
no clear histological changes (data not shown). In addition
to the bladder histopathology, the DMSO-treated bladders
also exhibited a signiﬁcantly reduced number of inﬁltrating
eﬀector CD8+ T cells compared to the PBS-treated bladders
(Figure 3(a); P<. 001).
3.2.IntravesicalDMSOTreatmentReducesBladderProduction
of Inﬂammatory Factor mRNAs in Acute Autoimmune Cys-
titis. U R O - O V Am i c ea r ek n o w nt op r o d u c ean u m b e ro f
inﬂammatory factors in the bladder upon cystitis induction
such as IFN-γ,M C P - 1 ,N G F ,T N F - α, and IL-6 [14, 17].
Aberrant expression of these inﬂammatory factors could
reﬂect the abnormal activities of multiple cell types in
site including T cells, mast cells, urothelial cells, detrusor
muscle cells, and sensory neurons. To investigate whetherthe
improved bladder histopathology after intravesical DMSO
treatment was correlated with reduced bladder production
of inﬂammatory factors, total RNAs were extracted from
the bladders and analyzed by RT-PCR (Figure 3(b)). The
normal bladders expressed a basal level of MCP-1 and IL-
6m R N A sb u tn o tI F N - γ,N G F ,a n dT N F - α mRNAs at the
experimental setting (data not shown). Induction of cystitis
resulted in increased mRNA expression for all factors tested
asmanifestedinthecontrolPBS-treatedbladders.Compared
to the PBS-treated bladders the DMSO-treated bladders
showed reduced production of these mRNAs, although the
magnitude of the reduction varied among the mRNAs.
3.3.IntravesicalDMSOTreatmentReducesBladderHistopath-
ology in Chronic Autoimmune Cystitis. Due to the pres-
ence of deletion-escaped autoreactive OT-I CD8+ Tc e l l s4 Journal of Biomedicine and Biotechnology
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Figure 2: Intravesical DMSO treatment reduces bladder histopathology in acute autoimmune cystitis. Acute cystitis was induced and treated
in URO-OVA mice as shown in Figure 1. At day 10, the bladders were collected, prepared for histological cross-sections, and stained with
H&E solution. (a) The normal bladder showing unremarkable mucosa and muscularis. (b) The PBS-treated bladder showing remarkable
cellular inﬁltration, interstitial edema, and mucosal hyperemia in the lamina propria. (c) The DMSO-treated bladder showing scattered
cellular inﬁltration and minimum edema and hyperemia. The slides are representative of 5 bladders in each group. Magniﬁcation: ×40 for
the left pane and ×400 for the right panel.Journal of Biomedicine and Biotechnology 5
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Figure 3: Intravesical DMSO treatment reduces inﬁltrating eﬀector CD8+ T cells and bladder expression of inﬂammatory factor mRNAs in
acute autoimmune cystitis. (a) The DMSO-treated bladders show reduced inﬁltrating eﬀector CD8+ T cells. Bladder single-cell suspensions
were prepared, stained with anti-Thy1.1 and anti-CD8 antibodies, and analyzed by ﬂow cytometry. Gate was set on lymphocytes according
to scatter criteria. The number of double positive T cells per bladder is presented as mean ± standard deviation of 5 bladders. ∗P<. 001
(compared to the PBS-treated bladders). (b) The DMSO-treated bladders show reduced production of IFN-γ,M C P - 1 ,N G F ,T N F - α,a n d
IL-6 mRNAs. Bladder total RNAs were extracted and analyzed by RT-PCR for the indicated inﬂammatory factors. GAPDH was used as an
internal control. Three bladders for each of PBS- and DMSO-treated groups are presented. The results are representative of two separate
experiments consisting of 4-5 animals per group. M: 100bp ladder.
URO-OVA/OT-I mice can spontaneously develop bladder
inﬂammation at 10 weeks of age that sustains for at least
4 months [14]. To assess whether DMSO is eﬀective on
treating chronic autoimmune cystitis, URO-OVA/OT-I mice
were treated intravesically with 50% DMSO once weekly for
a total of 3 treatments starting at week 10 and sacriﬁced
for analysis 3 days after last treatment. Compared to the
PBS-treated bladders that exhibited predominant cellular
inﬁltration with mild edema (Figure 4(a);s c o r e :2 + ) ,t h e
DMSO-treatedbladdersshowedminimumhistopathological
c h a n g e st h a tr e t a i n e do v e rn e x t4w e e k st e s t e d( Figure 4(c);
score: < 1+). To investigate whether intravesical DMSO
might aﬀect the endogenous eﬀector T cells in site and thus
led to improved bladder histopathology, we transferred a
parallel set of mice with 5 × 106 naive OT-I splenocytes 7
days after last treatment. Mice were sacriﬁced for analysis 3
days after cell transfer. In our previous studies, we observed
that adoptive transfer of na¨ ıve OT-I splenocytes could trigger
an acute inﬂammatory response, resulting in severe bladder
inﬂammation in URO-OVA/OT-I mice (data not shown).
Similarly, in the present study URO-OVA/OT-I mice treated
withPBS,upontransferofnaiveOT-Isplenocytes,developed
severe acute bladder inﬂammation (Figure 4(b); score: 3+).
In contrast, URO-OVA/OT-I mice treated with DMSO
developed only mild bladder inﬂammation (Figure 4(d);
score: 1+), presumably due to the DMSO elimination of
endogenous autoreactive OT-I CD8+ T cells.
3.4. DMSO Impairs Eﬀector T Cell Viability In Vitro. To
test whether DMSO could directly aﬀect eﬀector T cells,
we incubated OT-I splenocytes with various concentrations
of DMSO (ranging 1.563%–75%) in vitro for 24 hours,
followed by analysis of cell viability using MTT assay.
Compared to control PBS-treated cells, the DMSO-treated
cells exhibited signiﬁcantly reduced cell growth in a dose-
dependent manner (Figure 5; P<. 05 for 1.563% DMSO and
P<. 001 for all other DMSO concentrations). The highest
cell growth inhibition (70.5%) was observed at 50% DMSO.
TheDMSOeﬀectwassopotentasa44.6%growthinhibition
was observed even at a very low DMSO concentration
(1.563%).
We further assessed the eﬀect of DMSO on the induction
of eﬀector T cell apoptosis. OT-I splenocytes were incubated
with various concentrations of DMSO (ranging 1.563%–
25%) for 2 hours, double stained with annexin V and pro-
pidium iodide, and analyzed by ﬂow cytometry (Figure 6).
Compared to the control PBS-treated cells (7.2% for double-
stained cells), DMSO-treated cells showed a marked increase
in the double-stained cell population in a dose-dependent6 Journal of Biomedicine and Biotechnology
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Figure 4: Intravesical DMSO treatment reduces bladder histopathology in chronic autoimmune cystitis. URO-OVA/OT-I mice were treated
intravesically with PBS (a) or 50% DMSO (c) once weekly for a total of 3 treatments starting at week 10 and sacriﬁced for analysis 3 days
after last treatment. The bladders were collected, prepared for histological cross-sections, and stained with H&E solution. A parallel set of
mice treated with PBS (b) or DMSO (d) were further transferred with 5 × 106 naive OT-I splenocytes 7 days after last treatment. Mice were
sacriﬁced 3 days after cell transfer and the bladders analyzed by histological H&E staining. The slides are representative of 5 bladders in each
group. Magniﬁcation: ×200 for the left pane and ×100 for the right panel.
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Figure 5: DMSO inhibits eﬀector T cell growth in vitro. OT-I splenocytes were prepared and incubated with indicated concentrations of
DMSO (ranging 1.563%–75%) for 24 hours. MTT assay was then used to assess cell viability. Percent of cell growth inhibition was calculated
and presented as mean ± standard deviation of 5 duplicate wells referring to the PBS-treated wells (100% growth). ∗= P<. 001 and ∗∗=
P<. 05 (compared to the PBS-treated cells). The results are representative of two separate experiments.Journal of Biomedicine and Biotechnology 7
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Figure 6: DMSO induces eﬀector T cell apoptotic death in vitro. OT-I splenocytes were prepared and incubated with indicated
concentrations of DMSO (ranging 1.563%–25%) for 2 hours. Cells were then double stained with FITC-annexin V and propidium iodide
(PI) and analyzed by ﬂow cytometry. Gate was set on lymphocytes according to scatter criteria. The percent of single- and double-stained
cells is indicated. The results are representative of two separate experiments.
manner (from 21.2% at 6.25% DMSO to 71% at 25%
DMSO).
4. Discussion
We evaluated the eﬀect of intravesical DMSO on treating
acute and chronic autoimmune cystitis developed in URO-
OVA mice and URO-OVA/OT-I mice, respectively, and
observed that DMSO was eﬀective in treating both types
of cystitis in these novel EAC models. Compared to the
control PBS-treated bladders, the DMSO-treated bladders
showed markedly reduced histopathology and expression
of inﬂammatory factor mRNAs. In addition, DMSO also
showed its direct impairment on eﬀector T cells as cells
treated with DMSO exhibited reduced growth and apoptotic
death in vitro.
The present EAC models mimic both acute and chronic
phases of IC/PBS in bladder histopathology. Unlike the
conventional EAC models that require immunization of
syngeneic bladder homogenates that contain a mixture of
bladder tissue antigens, both URO-OVA mice and URO-
OVA/OT-I mice express a deﬁned self-Ag (i.e., OVA) on the
urothelium and develop bladder inﬂammation upon intro-
duction of OVA-speciﬁc OT-I CD8+ T cells [14, 17]. Thus,
these transgenic EAC models are unique, allowing quality-
controlled studies generating predictable, reliable and repro-
ducible information on bladder inﬂammation. In addition,
the URO-OVA/OT-I cystitis model is particularly relevant
to the natural history of IC/PBS patients as this model
can spontaneously develop bladder inﬂammation over time
during the animal life span. Further studies will focus on
characterizing bladder functional changes such as voiding
alternations and pain in these transgenic EAC models.
Prior studies involving intravesical DMSO in animal
models are limited. It was observed that intravesical DMSO
could increase the pressure threshold in a protamine sulfate-
induced rat bladder hyperactivity model, suggesting its eﬀect
on desensitizing nociceptive bladder aﬀerent [26]. A separate
study also demonstrated that intravesical DMSO could
facilitate the desensitization of nociceptive bladder aﬀerent
via its stimulation of bladder reﬂex pathways in rats [31]. In
addition, Intravesical DMSO also showed its eﬀect on reduc-
ing urinary level of hyaluronic acid in a similar protamine
sulfate-induced rat model, suggesting that it could replenish
the damaged glycosaminoglycan (GAG) layer [27]. In this
study, we used transgenic mouse EAC models and observed
that intravesical DMSO reduced bladder histopathology
and expression of inﬂammatory factor mRNAs. All animal
studies are consistent with the clinical observations that
intravesical DMSO is beneﬁcial for the treatment of IC/PBS
patients [20–23]. Since little is known with regard to bladder
histological changes in response to intravesical DMSO, our
results provide such histological evidence for the eﬀect of
DMSO on treating the bladder disorders.
Excessive expression of inﬂammatory factors such as
NGF and IL-6 in the bladder is considered to be responsible
for the development and propagation of IC/PBS symptoms
[32, 33]. As a model for IC/PBS studies, the inﬂamed
bladders of URO-OVA mice expressed elevated NGF and
IL-6 mRNAs as well as other inﬂammatory factor mRNAs
including IFN-γ,M C P - 1 ,a n dT N F - α [14, 17]. These
increased mRNA expressions could reﬂect abnormality of
multiple cell types in site including T cells, mast cells,
urothelial cells, detrusor muscle cells, and sensory neurons.
Although the functional outcomes in response to intrav-
esical DMSO require further investigation in this model,
intravesical DMSO could reduce bladder production of the
inﬂammatory factors, suggesting the beneﬁcial eﬀects of
DMSO in antibladder inﬂammation and symptomatic relief.
In both URO-OVA and URO-OVA/OT-I cystitis models,
OT-I CD8+ T cells that express the OVA-speciﬁc TCR serve
as eﬀector T cells in cystitis induction [14, 17]. Studies
have shown that DMSO is inhibitory for various cell types
including T cells [34, 35]. In consistent with these studies, we
observed that DMSO directly impaired T cell viability and
caused T cell apoptotic death in vitro. Our observations on
intravesical DMSO treatment in the URO-OVA/OT-I cystitis
model also suggest the inhibitory eﬀect of DMSO in vivo.
Mice treated with intravesical DMSO remained minimum
bladder histopathology for 4 weeks tested without further8 Journal of Biomedicine and Biotechnology
treatment, presumably due to the DMSO elimination of
endogenous autoreactive OT-I CD8+ T cells. To support
this assumption, DMSO-treated URO-OVA/OT-I mice, after
adoptive transfer of na¨ ıve OT-I splenocytes, failed to develop
acute cystitis with severity comparable to that seen in PBS-
treated URO-OVA/OT-I mice. In addition to T cells, DMSO
may also aﬀect other inﬂammatory cell types in site. In fact,
the observed reduction of NGF, MCP-1, and IL-6 mRNAs
in the DMSO-treated bladders could suggest the inhibitory
eﬀe c to fD M S Oo na b n o r m a la c t i v a t i o no fs e n s o r yn e u r o n s ,
urothelial cells, mast cells, and detrusor muscle cells. Thus,
the overall anti-inﬂammatory eﬀects of DMSO may involve
in its inhibition on multiple inﬂammatory cell types in the
inﬂamed bladder.
Currently, intravesical instillation of DMSO is one of
the primary treatments for IC/PBS patients and one of
the only two FDA-approved treatments for IC/PBS. This
therapeutic method has proven to be feasible and eﬀective
in the treatment of this painful urinary condition. Our
presentstudyintransgenicEACmodelsprovideshistological
evidence for the eﬀect of intravesical DMSO and a potential
mechanism of DMSO action.
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